

Index to volume 33

Author index

A

- Abernethy DR, Greenblatt DJ, Ochs HR, Weyers D, Divoll M, Harmatz JS, Shader RI: Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives, 628
Adir J: *see* Josselson et al, 144
Alloza JL, Lasagna L: A comparison of drug product information in four national compendia, 269
Amery A: *see* Staessen et al, 556
Andreasen F, Jakobsen P, Kornerup HJ, Pedersen EB, Pedersen OL: Urine and plasma propranolol, 10
Aronoff GR: *see* Bunke et al, 66, 73
Aronow WS: *see* Drayer et al, 727
Arranto AJ: *see* Sotaniemi et al, 826
Atkinson AJ Jr, Lertora JLL, Kushner W, Chao GC, Nevin MJ: Efficacy and safety of *N*-acetylprocainamide in long-term treatment of ventricular arrhythmias, 565
Atterhög J-H: *see* Dahlström et al, 701
Axthelm T: *see* Schäfer-Korting et al, 283

B

- Banerjee SP: *see* Sundaresan et al, 776
Barnes RF: *see* Veith et al, 763
Bartle WR, Walker SE, Shapero T: Dose-dependent effect of cimetidine on phenytoin kinetics, 649
Bechtold H: *see* Morrison et al, 747
Becker KL: *see* Birnbaum et al, 294
Begg E: *see* Williams et al, 314
Behrendt DM: *see* Wagner et al, 577
Bell RD: *see* Wong et al, 460
Belz GG, Doering W, Munkes R, Matthews J: Interaction between digoxin and calcium antagonists and antiarrhythmic drugs, 410
Bennett J: *see* Long et al, 663
Benowitz NL: *see* Herning et al, 84
Benson GD: Acetaminophen in chronic liver disease, 95
Berg MJ: *see* Berlinger et al, 351

- Berlinger WG, Spector R, Goldberg MJ, Johnson GF, Quee CK, Berg MJ: Enhancement of theophylline clearance by oral activated charcoal, 351
Berning J: *see* Waldorff et al, 418
Bertilsson L: *see* Tomson et al, 58
Bertouch J: *see* Meffin et al, 813
Bilezikian JP: *see* Steinberg and Bilezikian, 163
Birnbaum J, DiBianco R, Becker KL, Muesing R, Costello RB, Singh SN, Gottdiener JS, Fletcher RD: Glucose and lipid metabolism during acebutolol and propranolol therapy of angina in nondiabetic patients, 294
Bjerre M: *see* Gram et al, 335
Bjornsson TD: *see* Mahony et al, 491
Blaschke TF: *see* Schulz et al, 360
Blombery P: *see* Ross et al, 429
Bloom KE, Brewer GJ, Magon AM, Wetterstroem N: Microsomal incubation test of potentially hemolytic drugs for glucose-6-phosphate dehydrogenase deficiency, 403
Blumberg A: *see* Stoeckel et al, 633
Bochner F: *see* Siebert et al, 367
Bock JL, Nelson JC, Gray S, Jatlow PI: Desipramine hydroxylation: Variability and effect of antipsychotic drugs, 322
—*see* Nelson et al, 183
Bolte E: *see* Larochelle et al, 343
Bowman WP: *see* Evans et al, 301
Brewer GJ: *see* Bloom et al, 403
Brier ME: *see* Bunke et al, 66, 73
Brooks PM: *see* Meffin et al, 813
Brown JE, McLeod AA, Shand DG: Evidence for cardiac β_2 -adrenoceptors in man, 424
Brown JL: *see* Chrysant et al, 741
Brown KF: *see* Shanks et al, 792
—*see* Walker et al, 510
Brown MJ: *see* Scriven et al, 710
Brown RD: *see* Chrysant et al, 741
Buch J: *see* Waldorff et al, 418
Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC: Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis, 66
—Mezlocillin kinetics in hepatic insufficiency, 73

Burckart GJ: *see* Meyer et al, 329
 Burke C: *see* Pickles et al, 178
 Burnham L: *see* Conrad et al, 133
 Byers JM III: *see* Conrad et al, 133

C

Caillé G: *see* du Souich et al, 585
 Cairnes DA: *see* Evans et al, 301
 Calil HM: *see* Ross et al, 429
 Cashman PMM: *see* Gould et al, 438
 Cesarini J-P: *see* Weiner et al, 77
 Chabner BA: *see* Kerr et al, 44
 Chait LD: *see* Henningfield et al, 806
 Chao GC: *see* Atkinson et al, 565
 Cho J-K: *see* Towell et al, 517
 Chrysant SG, Brown RD, Kem DC, Brown JL: Anti-hypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril, 741
 Clarke JM: *see* McInnes et al, 35
 Collins JM: *see* Kerr et al, 44
 Conrad KA, Byers JM III, Finley PR, Burnham L: Lidocaine elimination: Effects of metoprolol and of propranolol, 133
 Costello RB: *see* Birnbaum et al, 294
 Crom WR: *see* Evans et al, 301
 —*see* Yee et al, 668

D

Dahlström U, Atterhög J-H, Jorfeldt L: Hemodynamics and leg muscle metabolism at rest and during exercise in young healthy men after prenalterol, 701
 Damiani E: *see* Sega et al, 289
 Davies RO: *see* Dujovne et al, 172
 DiBianco R: *see* Birnbaum et al, 294
 Dick M II: *see* Wagner et al, 577
 Divoll M: *see* Abernethy et al, 628
 Dobrinska MR: *see* Dujovne et al, 172
 Doering W: *see* Belz et al, 410
 Dollery CT: *see* Scriven et al, 710
 Dorian P: *see* Long et al, 663
 Dorn M: *see* Weintraub et al, 621
 Drake JC: *see* Kerr et al, 44
 Drayer JIM, Gardin JM, Weber MA, Aronow WS: Cardiac muscle mass during vasodilation therapy of hypertension, 727
 Dreslinski GR: *see* Dunn et al, 139
 Duggan DE: *see* Dujovne et al, 172
 Dujovne CA, Pitterman A, Vincek WC, Dobrinska MR, Davies RO, Duggan DE: Enterohepatic circulation of sulindac and metabolites, 172
 Dunn FG, Oigman W, Messerli FH, Dreslinski GR, Reisin E, Frohlich ED: Hemodynamic effects of intravenous labetalol in essential hypertension, 139
 Dunne M: *see* English et al, 381

Du Souich P, Caillé G, Larochelle P: Enhancement of nadolol elimination by activated charcoal and antibiotics, 585
 —*see* Larochelle et al, 343
 Dziedzic SW, Elijovich F, Felton K, Yeager K, Krakoff LR: Effect of guanabenz on blood pressure responses to posture and exercise, 151

E

Ebert MH: *see* Martin et al, 19
 Eckardt B: *see* Ochs et al, 471
 Egeblad H: *see* Waldorff et al, 418
 Elijovich F: *see* Dziedzic et al, 151
 English J, Dunne M, Marks V: Diurnal variation in prednisolone kinetics, 381
 Erkkola R: *see* Kanto et al, 786
 Eshelman FN: *see* Garg et al, 445
 Evans WE, Hutson PR, Stewart CF, Cairnes DA, Bowman WP, Rivera G, Crom WR: Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion, 301
 —*see* Yee et al, 668

F

Fagard R: *see* Staessen et al, 556
 Fahmy NR, Sunder N, Soter NA: Role of histamine in the hemodynamic and plasma catecholamine responses to morphine, 615
 Feely J, Wood AJJ: Effect on apparent liver blood flow of histamine-receptor blockers and inhibition of prostaglandin synthesis, 91
 —*see* Wells et al, 603
 Felton K: *see* Dziedzic et al, 151
 Field J: *see* Siebert et al, 367
 Finley PR: *see* Conrad et al, 133
 Fish A: *see* Pickles et al, 178
 Fletcher RD: *see* Birnbaum et al, 294
 Frantz M: *see* Swabb et al, 609
 Frohlich ED: *see* Dunn et al, 139
 Fung H-L: *see* Morrison et al, 747

G

Gabb BW: *see* Siebert et al, 367
 Galeazzi RL, Pirovino M, Weidmann P: Constant kinetics and constant concentration-effect relationship during long-term blockade with pindolol, 733
 Gardin JM: *see* Drayer et al, 727
 Garg DC, Weidler DJ, Eshelman FN: Ranitidine bioavailability and kinetics in normal male subjects, 445
 Giacomini KM: *see* Schults et al, 360
 Giles HG: *see* Long et al, 663
 Golas C: *see* Rajchgot et al, 551
 Goldberg MJ: *see* Berlinger et al, 351
 Good F: *see* Rajchgot et al, 551

- Gordon EK: *see* Martin et al, 19
Gottdiener JS: *see* Birnbaum et al, 294
Gould BA, Hornung RS, Kieso HA, Cashman PMM, Raftery EB: An intra-arterial profile of methyl dopa, 438
Goyer R: *see* Laroche et al, 343
Gram LF, Bjerre M, Kragh-Sorensen P, Kvinesdal B, Molin J, Pedersen OL, Reisby N: Imipramine metabolites in blood of patients during therapy and after overdose, 335
Grant DM, Tang BK, Kalow W: Polymorphic N-acetylation of a caffeine metabolite, 355
Grant DM, Tang BK, Kalow W: Variability in caffeine metabolism, 591
Grauwels R: *see* Staessen et al, 556
Gray S: *see* Bock et al, 322
Greenblatt DJ: *see* Abernethy et al, 628
—*see* Ochs et al, 471
Griffiths RR: *see* Henningfield et al, 806
Gritz ER: *see* Shiffman et al, 800
Groothold G: *see* Segal et al, 289
Gross M: *see* Zweifler et al, 156
Gumbrecht G: *see* Veith et al, 763
Gundert-Remy U, Hildebrandt R, Stiehl A, Weber E: Nonlinear mefloquine kinetics due to dose-dependent metabolism, 656

H

- Halter JB: *see* Veith et al, 763
Hansen PB: *see* Waldorff et al, 418
Harding E: *see* Rajchgot et al, 551
Harmatz JS: *see* Abernethy et al, 628
Harmatz JS: *see* Ochs et al, 471
Harrington BJ: *see* Meffin et al, 813
Hasday JD: *see* Sundaresan et al, 776
Hassan S: *see* Pickles et al, 178
Hees P: *see* Wagner et al, 577
Henningfield JE, Chait LD, Griffiths RR: Cigarette smoking and subjective response in alcoholics: Effects of pentobarbital, 806
Herning RI, Jones RT, Benowitz NL, Mines AH: How a cigarette is smoked determines blood nicotine levels, 84
Hershey LA: *see* Sundaresan et al, 776
Hildebrandt R: *see* Gundert-Remy et al, 656
Himberg J-J: *see* Kanto et al, 786
Hilde M: *see* Semplicini et al, 278
Hömann D: *see* Morrison et al, 747
Holcombe BJ: *see* Meyer et al, 329
Holley FO, Magliozzi JR, Stanski DR, Lombrozo L, Hollister LE: Haloperidol kinetics after oral and intravenous doses, 477
Hollister LE: *see* Holley et al, 477
—*see* Nakano and Hollister, 453
Hoppe-Seyler G: *see* Stoeckel et al, 633
Hornung RS: *see* Gould et al, 438
Horwitz D: *see* Izzo et al, 102

- Hrdina PD, Lapierre YD, McIntosh B, Oyewumi LK: Mianserin kinetics in depressed patients, 757
Hutson PR: *see* Evans et al, 301
Hutt PB: Investigations and reports respecting FDA regulation of new drugs (Part I), 537
—Investigations and reports respecting FDA regulation of new drugs (Part II), 674

I

- Imhoff DM: *see* Siebert et al, 367
Inaba T, Vinks A, Otton SV, Kalow W: Comparative pharmacogenetics of sparteine and debrisoquine, 394
Izzo JL Jr, Horwitz D, Lawton WJ, Keiser HR: Fludrocortisone suppression of sympathetic nervous activity, 102

J

- Jähnchen E: *see* Morrison et al, 747
Jakobsen P: *see* Andreassen et al, 10
Jarboe CH: *see* May and Jarboe, 822
Jarvik ME: *see* Shiffman et al, 800
Jatlow PI: *see* Bock et al, 322
—*see* Nelson et al, 183
Johnson GF: *see* Berlinger et al, 351
Jolivet J: *see* Kerr et al, 44
Jones RT: *see* Herning et al, 84
Jorfeldt L: *see* Dahlström et al, 701
Josselson J, Narang PK, Adir J, Yacobi A, Sadler JH: Bretylium kinetics in renal insufficiency, 144

K

- Kalow W: *see* Grant et al, 355, 591
—*see* Inaba et al, 394
Kangas L: *see* Kanto et al, 786
Kanto J, Sjövall S, Erkkola R, Himberg J-J, Kangas L: Placental transfer and maternal midazolam, 786
Kärkkäinen S: *see* Neuvonen and Kärkkäinen, 386
Kates RE, Keefe DL, Winkle RA: Lorainide disposition kinetics in arrhythmia patients, 28
Keefe DL: *see* Kates et al, 28
Keiser HR: *see* Izzo et al, 102
Keller E: *see* Stoeckel et al, 633
Kem DC: *see* Chrysant et al, 741
Kerr IG, Jolivet J, Collins JM, Drake JC, Chabner BA: Test dose for predicting high-dose methotrexate infusions, 44
Kieso HA: *see* Gould et al, 438
King KC: *see* Tserng et al, 522
Kirch W: *see* Schäfer-Korting et al, 283
Kitanaka I: *see* Ross et al, 429
Kjærgård H: *see* Waldorff et al, 418
Köhler H: *see* Schäfer-Korting et al, 283

Kopin IJ: *see* Martin et al, 19

—*see* Ross et al, 429

Kornerup HJ: *see* Andreasen et al, 10

Kragh-Sorensen P: *see* Gram et al, 335

Krakoff LR: *see* Dziedzic et al, 151

Kroening BH: *see* Sundaresan et al, 776

Kushner W: *see* Atkinson et al, 565

Kvinesdal B: *see* Gram et al, 335

L

Lapierre YD: *see* Hrdina et al, 757

Larochelle P, DuSouich P, Bolte E, Leloir J, Goyer R: Tixocortol pivalate, a corticosteroid with no systemic glucocorticoid effect after oral, intrarectal, and intranasal application, 343

—*see* DuSouich et al, 585

Larsen A, Storstein L: Digitoxin kinetics and renal excretion in children, 717

Lasagna L: *see* Alloza and Lasagna, 269

—*see* May et al, 691

Laska EM, Sunshine A, Zigelboim I, Roure C, Marrero I, Wanderling J, Olson N: Effect of caffeine on acetaminophen analgesia, 498

Lawton WJ: *see* Izzo et al, 102

Lee FH: *see* Yee et al, 668

Lee MA: *see* Shiffman et al, 800

Leloir J: *see* Larochelle et al, 343

Lertora JLL: *see* Atkinson et al, 565

Levy G: *see* Morris and Levy, 529

Levy M, Zylber-Katz E: Caffeine metabolism and coffee-attributed sleep disturbances, 770

Libretti A: *see* Segal et al, 289

Lijnen P: *see* Staessen et al, 556

Linnoila M: *see* Ross et al, 429

Lloyd JV: *see* Siebert et al, 367

Loch MH: *see* Loch et al, 642

Loch WE: *see* Loch et al, 642

Loch WEE, Wenger AP, Loch MH, Loch WE, Reiriz HML: Local aspirin analgesia in the oral cavity, 642

Lockwood GF: *see* Wagner et al, 577

Löfdahl C-G, Marlin GE, Svedmyr N: Pafenolol, a highly selective β_1 -adrenoceptor-antagonist, in asthmatic patients: Interaction with terbutaline, 1

Lombrozo L: *see* Holley et al, 477

Long JP, Giles HG, Bennett J, Dorian P, Thiessen JJ, Orrego H, Sellers EM: Effect of alcohol on propylthiouracil disposition, 663

Ludden TM: *see* Wong et al, 460

Luft FC: *see* Bunke et al, 66, 73

M

MacLeod S: *see* Rajchgot et al, 551

Macquin I: *see* Scriven et al, 710

Magliozzi JR: *see* Holley et al, 477

Magon AM: *see* Bloom et al, 403

Mahony C, Wolfram KM, Nash PV, Bjornsson TD: Kinetics and metabolism of sulfinpyrazone, 491

Mailland F: *see* Segal et al, 289

Maltese J: *see* Shiffman et al, 800

Marks V: *see* English et al, 381

Marlin GE: *see* Löfdahl et al, 1

Marrero I: *see* Laska et al, 498

Martin PR, Ebert MH, Gordon EK, Kopin IJ: Urinary catecholamine metabolites and effects of clonidine in patients with alcohol amnesic disorder, 19

Matthews J: *see* Belz et al, 410

May DC, Jarboe CH: Effect of probenecid on dihydropyridine elimination, 822

May MS, Wardell WM, Lasagna L: New drug development during and after a period of regulatory change: Clinical research activity of major United States pharmaceutical firms, 1958 to 1979, 691

McDevitt DG: *see* Salem and McDevitt, 52

McGowan FX, Reiter MJ, Pritchett ELC, Shand DG: Verapamil plasma binding: Relationship to α_1 -acid glycoprotein and drug efficacy, 485

McInnes GT, Clarke JM, Shelton JR: Dose-response relationships for spironolactone in combination with a potassium-wasting diuretic, 35

McIntosh B: *see* Hrdina et al, 757

McLeod AA: *see* Brown et al, 424

McNamara PJ: *see* Stoekel et al, 633

Meffin PJ, Brooks PM, Bertouch J, Veenendaal JR, Harrington BJ: Diflunisal disposition and hypouricemic response in osteoarthritis, 813

Meinertz T: *see* Morrison et al, 741

Messerli FH: *see* Dunn et al, 139

Meyer MC, Holcombe BJ, Burckart GJ, Raghow G, Yau MK: Nonlinear ethotoin kinetics, 329

Mines AH: *see* Herning et al, 84

Molin J: *see* Gram et al, 335

Morandini F: *see* Semplicini et al, 278

Morris ME, Levy G: Serum concentration and renal excretion by normal adults of inorganic sulfate after acetaminophen, ascorbic acid, or sodium sulfate, 529

Morrison RA, Wiegand U-W, Jähnchen E, Höhmann D, Bechtold H, Meinertz T, Fung H-L: Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina, 747

Muesing R: *see* Birnbaum et al, 294

Munkes R: *see* Belz et al, 410

Murphy MB: *see* Scriven et al, 710

Mutschler E: *see* Schäfer-Korting et al, 283

N

Nahata MC, Powell DA: Chloramphenicol serum concentration falls during chloramphenicol succinate dosing, 308

- Nakano S, Hollister LE: Chronopharmacology of amitriptyline, 453
Narang PK: *see* Josselson et al, 144
Nash PV: *see* Mahony et al, 491
Nelson JC, Bock JL, Jatlow PI: Clinical implications of 2-hydroxydesipramine plasma concentrations, 183
—*see* Bock et al, 322
Neuvonen PJ, Kärkkäinen S: Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics, 386
Nevin MJ: *see* Atkinson et al, 565

O

- Ochs HR, Greenblatt DJ, Eckardt B, Harmatz JS, Shader RI: Repeated diazepam dosing in cirrhotic patients: Cumulation and sedation, 471
—*see* Abernethy et al, 628
O'Grady J: *see* Pickles et al, 178
Oigman W: *see* Dunn et al, 139
Olson N: *see* Laska et al, 498
Orrego H: *see* Long et al, 663
O'Shea K: *see* Williams et al, 314
Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG: Reduction in oral penicillamine absorption by food, antacid, and ferrous sulfate, 465
Otton SV: *see* Inaba et al, 394
Oyewumi LK: *see* Hrdina et al, 757

P

- Patel RB: *see* Osman et al, 465
Pedersen EB: *see* Andreassen et al, 10
Pedersen OL: *see* Andreassen et al, 10
—*see* Gram et al, 335
Pelkonen O: *see* Vähäkangas et al, 375
Pessina AC: *see* Semplicini et al, 278
Pickles H, Fish A, Hassan S, Burke C, Warrington S, O'Grady J: Effects of intravenous epoprostenol on platelets and the cardiovascular system are not potentiated by dipyridamole, 178
Pirovino M: *see* Galeazzi et al, 733
Pitterman A: *see* Dujovne et al, 172
Platt TB: *see* Swabb et al, 609
Potter WZ: *see* Ross et al, 429
Powell DA: *see* Nahata and Powell, 308
Pritchett ELC: *see* McGowan et al, 485
Prober CG: *see* Rajchgot et al, 551

Q

- Quee CK: *see* Berlinger et al, 351

R

- Raftery EB: *see* Gould et al, 438
Raghow G: *see* Meyer et al, 329
Rajchgot P, Prober CG, Soldin SJ, Good F, Harding E, Golas C, MacLeod S: Toward optimization of therapy in the neonate, 551

- Ramzan IM: *see* Shanks et al, 792
Raskind MA: *see* Veith et al, 763
Reiriz HML: *see* Loch et al, 642
Reisby N: *see* Gram et al, 335
Reisn E: *see* Dunn et al, 139
Reiter MJ: *see* McGowan et al, 485
Ritchie JL: *see* Veith et al, 763
Rivera G: *see* Evans et al, 301
Roh BL: *see* Towell et al, 517
Ross RJ, Zavdil AP III, Calil HM, Linnoila M, Kitanaka I, Blombery P, Kopin IJ, Potter WZ: Effects of desmethylimipramine on plasma norepinephrine, pulse, and blood pressure, 429
Rossi GP: *see* Semplicini et al, 278
Roure C: *see* Laska et al, 498

S

- Sadler JH: *see* Josselson et al, 144
Sakmar E: *see* Wagner et al, 577
Salem SA, McDevitt DG: Central effects of beta-adrenoceptor antagonists, 52
Schäfer-Korting M, Kirch W, Axthelm T, Köhler H: Atenolol interaction with aspirin, allopurinol, and ampicillin, 283
Schewach-Millet M: *see* Weiner et al, 77
Schneider NG: *see* Shiffman et al, 800
Schulz P, Turner-Tamiasu K, Smith G, Giacomini KM, Blaschke TF: Amitriptyline disposition in young and elderly normal men, 360
Schuna A: *see* Osman et al, 465
Scriven AJI, Dollery CT, Murphy MB, Macquin I, Brown MJ: Blood pressure and plasma norepinephrine concentrations after endogenous norepinephrine release by tyramine, 710
Sega R, Mailland F, Damiani E, Groothold G, Libretti A: Indenolol in hypertension, 289
Sellers EM: *see* Long et al, 663
Semah D: *see* Weiner et al, 77
Semplicini A, Pessina AC, Rossi GP, Hlede M, Morandin F: Alpha-adrenoceptor blockade by labetalol during long-term dosing, 278
Shader RI: *see* Abernethy et al, 628
—*see* Ochs et al, 471
Shand DG: *see* Brown et al, 424
—*see* McGowan et al, 485
Shanks C: *see* Walker et al, 510
Shanks CA, Ramzan IM, Walter JS, Brown KF: Galamine disposition in open-heart surgery involving cardiopulmonary bypass, 792
Shapero T: *see* Bartle et al, 649
Shelton JR: *see* McInnes et al, 35
Shiffman SM, Gritz ER, Maltese J, Lee MA, Schneider NG, Jarvik ME: Effects of cigarette smoking and oral nicotine on hand tremor, 800
Siebert DJ, Bochner F, Imhoff DM, Watts S, Lloyd JV, Field J, Gabb BW: Aspirin kinetics and platelet aggregation in man, 367

- Singh SN: *see* Birnbaum et al, 294
 Sisson J: *see* Zweifler et al, 156
 Sjövall S: *see* Kanto et al, 786
 Sloan RS: *see* Bunke et al, 66, 73
 Smith G: *see* Schulz et al, 360
 Smyth RD: *see* Yee et al, 668
 Soldin SJ: *see* Rajchgot et al, 551
 Sotaniemi E, Arranto AJ, Sutinen S, Stengård JH, Sutinen S: Treatment of noninsulin-dependent diabetes mellitus with enzyme inducers, 826
 —*see* Vähäkangas et al, 375
 Soter NA: *see* Fahmy et al, 615
 Spector R: *see* Berlinger et al, 351
 Sriwatanakul K: *see* Weintraub et al, 621
 Staessen J, Fagard R, Grauwels R, Lijnen P, Verschueren LJ, Amery A: Effects of tibolone, a new α -adrenoceptor antagonist, in essential hypertension, 556
 Stanski DR: *see* Holley et al, 477
 Steinberg SF, Bilezikian JP: Total and free propranolol levels in sensitive and resistant patients, 163
 Steiness E: *see* Waldorff et al, 418
 Stengård JH: *see* Sotaniemi et al, 826
 Stern M: *see* Swabb et al, 609
 Stewart CF: *see* Evans et al, 301
 Stiehl A: *see* Gundert-Remy et al, 656
 Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E: Single-dose ceftriaxone kinetics in functionally anephric patients, 633
 Storstein L: *see* Larsen and Storstein, 717
 Sugerman AA: *see* Swabb et al, 609
 Sundaresan PR, Weintraub M, Hershey LA, Kroening BH, Hasday JD, Banerjee SP: Platelet α -adrenergic receptors in obesity: Alteration with weight loss, 776
 —*see* Weintraub et al, 621
 Sunder N: *see* Fahmy et al, 615
 Sundstrom WR: *see* Osman et al, 465
 Sunshine A: *see* Laska et al, 498
 Sutinen S: *see* Sotaniemi et al, 826
 Svedmyr N: *see* Löfdahl et al, 1
 Swabb EA, Sugerman AA, Frantz M, Platt TB, Stern M: Renal handling of the monobactam azthreonam in healthy subjects, 609

T

- Takieddine FN: *see* Tserng et al, 522
 Tang BK: *see* Grant et al, 355, 591
 Thiessen JJ: *see* Long et al, 663
 Tomson T, Tybring G, Bertilsson L: Single-dose kinetics and metabolism of carbamazepine-10, 11-epoxide, 58
 Towell JF III, Cho J-K, Roh BL, Wang RIH: Disulfiram and erythrocyte aldehyde dehydrogenase inhibition, 517
 Tserng K-Y, Takieddine FN, King KC: Developmental aspects of theophylline metabolism in premature infants, 522
 Turner-Tamiasu K: *see* Schulz et al, 360
 Tybring G: *see* Tomson et al, 58

V

- Vähäkangas K, Pelkonen O, Sotaniemi E: Cigarette smoking and drug metabolism, 375
 Veenendaal JR: *see* Meffin et al, 813
 Veith RC, Raskind MA, Barnes RF, Gumbrecht G, Ritchie JL, Halter JB: Tricyclic antidepressants and supine, standing, and exercise plasma norepinephrine levels, 763
 Verschueren LJ: *see* Staessen et al, 556
 Vincek WC: *see* Dujovne et al, 172
 Vinks A: *see* Inaba et al, 394

W

- Wade D: *see* Williams et al, 314
 Wagner JG, Dick M II, Behrendt DM, Lockwood GF, Sakmar E, Hees P: Determination of myocardial and serum digoxin concentrations in children by specific and nonspecific assay methods, 577
 Waldorff S, Hansen PB, Egeblad H, Berning J, Buch J, Kjærgård H, Steiness E: Interactions between digoxin and potassium-sparing diuretics, 418
 Walker JS, Shanks C, Brown KF: Alcuronium kinetics and plasma concentration-effect relationship, 510
 —*see* Shanks et al, 792
 Walker SE: *see* Bartle et al, 649
 Wanderling J: *see* Laska et al, 498
 Wang RIH: *see* Towell et al, 517
 Wardell WM: *see* May et al, 691
 Warrington S: *see* Pickles et al, 178
 Watts S: *see* Siebert et al, 367
 Weber E: *see* Gundert-Remy et al, 656
 Weber MA: *see* Drayer et al, 727
 Weidler DJ: *see* Garg et al, 445
 Weidmann P: *see* Galeazzi et al, 733
 Weiner M, Semah D, Schewach-Millet M, Cesarini J-P: Preclinical and clinical evaluation of topical acid products for skin tumors, 77
 Weintraub M, Sriwatanakul K, Sundaresan PR, Weis OF, Dorn M: Extended-release fenfluramine: Patient acceptance and efficacy of evening dosing, 621
 —*see* Sundaresan et al, 776
 Weis OF: *see* Weintraub et al, 621
 Welling PG: *see* Osman et al, 465
 Wells PG, Feely J, Wilkinson GR, Wood AJJ: Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long-term dosing, 603
 Wenger AP: *see* Loch et al, 642
 Wetterstroem N: *see* Bloom et al, 403
 Weyers D: *see* Abernethy et al, 628
 Wiegand U-W: *see* Morrison et al, 747
 Wilkinson GR: *see* Wells et al, 603

- Williams K, Begg E, Wade D, O'Shea K: Effects of phenytoin, phenobarbital, and ascorbic acid on misonidazole elimination, 314
Winkle RA: *see* Kates et al, 28
Wolfram KM: *see* Mahony et al, 491
Wong YY, Ludden TM, Bell RD: Effect of erythromycin on carbamazepine kinetics, 460
Wood AJJ: *see* Feely and Wood, 91
—*see* Wells et al, 603

Y

- Yacobi A: *see* Josselson et al, 144
Yau MK: *see* Meyer et al, 329

- Yeager K: *see* Dziedzic et al, 151
Yee GC, Crom WR, Lee FH, Smyth RD, Evans WE: Bleomycin disposition in children with cancer, 668

Z

- Zavadil AP III: *see* Ross et al, 429
Zigheboim I: *see* Laska et al, 498
Zweifler A, Gross M, Sisson J: Effect of phenoxybenzamine on cardiovascular and plasma catecholamine responses to clonidine, 156
Zylber-Katz E: *see* Levy and Zylber-Katz, 770

Subject index

A

- Acarbase (USAN list No. 234), 401
- Acceptance, patient, and efficacy of evening dosing with extended-release fenfluramine (Weintraub et al), 621
- Acebutolol and propranolol therapy of angina in nondiabetic patients, glucose and lipid metabolism during (Birnbaum et al), 294
- Acetaminophen analgesia, effect of caffeine on (Laska et al), 498
- ascorbic acid, or sodium sulfate, serum concentration and renal excretion by normal adults of inorganic sulfate after (Morris and Levy), 529
- in chronic liver disease (Benson), 95
- Activated charcoal and antibiotics, enhancement of nadolol elimination by (Du Souich et al), 585
- oral, enhancement of theophylline clearance by (Berlinger et al), 351
- Alcohol amnestic disorder, urinary catecholamine metabolites and effects of clonidine in patients with (Martin et al), 19
- effect of, on propylthiouracil disposition (Long et al), 663
- Alcoholics, cigarette smoking and subjective response in, effects of pentobarbital on (Henningfield et al), 806
- Alcuronium kinetics and plasma concentration-effect relationship (Walker et al), 510
- Allopurinol, ampicillin, and aspirin, atenolol interaction with (Schäfer-Korting et al), 283
- Alpha-1-acid glycoprotein and drug efficacy, relationship to, verapamil plasma binding (McGowan et al), 485
- Alpha-adrenergic receptors, platelet, in obesity: alteration with weight loss (Sundaresan et al), 776
- Alpha-adrenoceptor antagonist, tibalosine, effects of, in essential hypertension, (Staessen et al), 556
- blockade by labetalol during long-term dosing (Semplicini et al), 278
- Ambulatory peritoneal dialysis, continuous, cefazolin and cephalixin kinetics in (Bunke et al), 66
- American Society for Clinical Pharmacology and Therapeutics, abstracts of papers, 193
- meeting program, 111
- message from president, 109
- notes of, 402, 829
- Amitriptyline, chronopharmacology of (Nakano and Hollister), 453
- disposition in young and elderly normal men (Schulz et al), 360
- Ammonium chloride, charcoal, and sodium bicarbonate, effects of, on chlorpropamide kinetics (Neuvonen and Kärkkäinen), 386
- Ampicillin, aspirin, and allopurinol, atenolol interaction with (Schäfer-Korting et al), 283
- Analgesia, acetaminophen, effect of caffeine on (Laska et al), 498
- local, aspirin, in the oral cavity (Loch et al), 642
- Anephric patients, functionally, single-dose ceftriaxone kinetics in (Stoeckel et al), 633
- Angina in nondiabetic patients, glucose and lipid metabolism during acebutolol and propranolol therapy of (Birnbaum et al), 294
- intravenous, sublingual, and percutaneous dosing in, isosorbide dinitrate kinetics and dynamics after (Morrison et al), 747
- Antacid, food, and ferrous sulfate, reduction in oral penicillamine absorption by (Osman et al), 465
- Antagonist(s), α -adrenoceptor, tibalosine, effects of, in essential hypertension (Staessen et al), 556
- beta-adrenoceptor, central effects of (Salem and McDevitt), 52

- Antiarrhythmic drugs, interaction between digoxin and calcium antagonists and (Belz et al), 410
- Antibiotics, activated charcoal and, enhancement of nadolol elimination by (Du Souich et al), 585
- Antidepressants, tricyclic, and supine, standing, and exercise plasma norepinephrine levels (Veith et al), 763
- Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril (Chrysant et al), 741
- Antipsychotic drugs, variability and effect of, on desipramine hydroxylation (Bock et al), 322
- Apparent liver blood flow, effect on, of histamine-receptor blockers and inhibition of prostaglandin synthesis (Feely and Wood), 91
- Arrhythmia(s), ventricular, efficacy and safety of *N*-acetylprocainamide in long-term treatment of (Atkinson et al), 565
- patients, lorcaïnide disposition kinetics in (Kates et al), 28
- Ascorbic acid, acetaminophen, or sodium sulfate, serum concentration and renal excretion by normal adults of inorganic sulfate after (Morris and Levy), 529
- phenytoin, and phenobarbital, effects of, on misonidazole elimination (Williams et al), 314
- Aspirin, allopurinol, and ampicillin, atenolol interaction with (Schäfer-Korting et al), 283
- analgesia, local, in the oral cavity (Loch et al), 642
- kinetics and platelet aggregation in man (Siebert et al), 367
- Assay methods, specific and nonspecific, determination of myocardial and serum digoxin concentrations in children by (Wagner et al), 577
- Associates of Clinical Pharmacology, meeting program, 130
- Asthmatic patients, pafenolol, a highly selective β_1 -adrenoceptor-antagonist in: interaction with terbutaline (Löfdahl et al), 1
- Atenolol interaction with aspirin, allopurinol, and ampicillin (Schäfer-Korting et al), 283
- Atracurium besylate (USAN list No. 234), 401
- Azthreonam, the monobactam, renal handling of, in healthy subjects (Swabb et al), 609
- Aztreonam (USAN list No. 235), 549

B

- Beta-adrenoceptor antagonists, central effects of (Salem and McDevitt), 52
- Beta₁-adrenoceptor-antagonist, pafenolol, a highly selective, in asthmatic patients: interaction with terbutaline (Löfdahl et al), 1
- Beta₂-adrenoceptors in man, cardiac, evidence for (Brown et al), 424
- Bioavailability and kinetics, ranitidine, in normal male subjects (Garg et al), 445

- Bleomycin disposition in children with cancer (Yee et al), 668
- Blockade, alpha-adrenoceptor, by labetalol during long-term dosing (Semplicini et al), 278
- long-term, with pindolol, constant kinetics and constant concentration-effect relationship during (Galeazzi et al), 733
- Blood flow, liver, and propranolol disposition, effect of thyrotoxicosis on, after long-term dosing (Wells et al), 603
- nicotine levels, how a cigarette is smoked determines (Herning et al), 84
- of patients during therapy and after overdose, imipramine metabolites in (Gram et al), 335
- pressure and plasma norepinephrine concentrations after endogenous norepinephrine release by tyramine (Scriven et al), 710
- pulse, effects of desmethylinipramine on (Ross et al), 429
- responses to posture and exercise, effect of guanabenz on (Dziedzic et al), 151
- Books received, 192, 690
- Bretylum kinetics in renal insufficiency (Josselson et al), 144
- Bromadoline maleate (USAN list No. 237), 826
- Brotizolam (USAN list No. 232), 108
- Bypass, cardiopulmonary, open-heart surgery involving, gallamine disposition in (Shanks et al), 792

C

- Caffeine, effect of, on acetaminophen analgesia (Laska et al), 498
- metabolism and coffee-attributed sleep disturbances (Levy and Zylber-Katz), 770
- variability in (Grant et al), 591
- metabolite, polymorphic *N*-acetylation of a (Grant et al), 355
- Calcium antagonists, digoxin and, and antiarrhythmic drugs, interaction between (Belz et al), 410
- Cancer, children with, bleomycin disposition in (Yee et al), 668
- Caracemide (USAN list No. 237), 827
- Carbamazepine-10,11-epoxide, single-dose kinetics and metabolism of (Tomson et al), 58
- kinetics, effect of erythromycin on (Wong et al), 460
- Carboplatin (USAN list No. 232), 108
- Cardiac β_2 -adrenoceptors in man, evidence for (Brown et al), 424
- muscle mass during vasodilation therapy of hypertension (Drayer et al), 727
- Cardiopulmonary bypass, open-heart surgery involving, gallamine disposition in (Shanks et al), 792
- Cardiovascular and plasma catecholamine responses to clonidine, effect of phenoxybenzamine on (Zweifel et al), 156

- Cardiovascular—cont'd
 system, platelets and the, effects of intravenous epoprostenol on, are not potentiated by dipyridamole (Pickles et al), 178
- Catecholamine metabolites, urinary, and effects of clonidine in patients with alcohol amnesic disorder (Martin et al), 19
 responses to morphine, hemodynamic and plasma, role of histamine in (Fahmy et al), 615
- Cavity, oral, local aspirin analgesia in (Loch et al), 642
- Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis (Bunke et al), 66
- Ceftriaxone, single-dose, kinetics in functionally anephric patients (Stoeckel et al), 633
- Celiprolol hydrochloride (USAN list No. 233), 190
- Central effects of beta-adrenoceptor antagonists (Salem and McDevitt), 52
- Cephalexin, cefazolin and, kinetics in continuous ambulatory peritoneal dialysis (Bunke et al), 66
- Cerebrospinal fluid, methotrexate, and serum concentrations after intermediate-dose methotrexate infusion (Evans et al), 301
- Charcoal, activated, and antibiotics, enhancement of nadolol elimination by (Du Souich et al), 585
 sodium bicarbonate, and ammonium chloride, effects of, on chlorpropamide kinetics (Neuvonen and Kärkkäinen), 386
- Children, determination of myocardial and serum digoxin concentrations in, by specific and nonspecific assay methods (Wagner et al), 577
 digitoxin kinetics and renal excretion in (Larsen and Storstein), 717
 with cancer, bleomycin disposition in (Yee et al), 668
- Chloramphenicol serum concentration falls during chloramphenicol succinate dosing (Nahata and Powell), 308
 succinate dosing, chloramphenicol serum concentration falls during (Nahata and Powell), 308
- Chlorpropamide kinetics, effects of charcoal, sodium bicarbonate, and ammonium chloride on (Neuvonen and Kärkkäinen), 386
- Chronopharmacology of amitriptyline (Nakano and Hollister), 453
- Cigarette is smoked, how a, determines blood nicotine levels (Herning et al), 84
 smoking and drug metabolism (Vähäkangas et al), 375
 and oral nicotine, effects of, on hand tremor (Shiffman et al), 800
 and subjective response in alcoholics: effects of pentobarbital (Henningfield et al), 806
- Cimetidine, dose-dependent effects of, on phenytoin kinetics (Bartle et al), 649
- Circulation, enterohepatic, of sulindac and metabolites (Dujovne et al), 172
- Cirrhotic patients, repeated diazepam dosing in: cumulation and sedation (Ochs et al), 471
- Clinical implications of 2-hydroxydesipramine plasma concentrations (Nelson et al), 183
 preclinical and, evaluation of topical acid products for skin tumors (Weiner et al), 77
 research activity of major United States pharmaceutical firms, 1958 to 1979, new drug development during and after a period of regulatory change (May et al), 691
- Clonidine, cardiovascular and plasma catecholamine responses to, effect of phenoxybenzamine on (Zweifler et al), 156
 urinary catecholamine metabolites and effects of, in patients with alcohol amnesic disorder (Martin et al), 19
- Clorsulon (USAN list No. 232), 108
- Coffee-attributed sleep disturbances, caffeine metabolism and (Levy and Zylber-Katz), 770
- Comparative pharmacogenetics of sparteine and debrisoquine (Inaba et al), 394
- Comparison of drug product information in four national compendia (Alloza and Lasagna), 269
- Concentration(s), myocardial and serum digoxin, determination of, by specific and nonspecific assay methods (Wagner et al), 577
 -effect relationship, constant, constant kinetics and, during long-term blockade with pindolol (Galeazzi et al), 733
 plasma norepinephrine, blood pressure and, after endogenous norepinephrine release by tyramine (Scriven et al), 710
- Constant kinetics and constant concentration-effect relationship during long-term blockade with pindolol (Galeazzi et al), 733
- Continuous ambulatory peritoneal dialysis, cefazolin and cephalexin kinetics in (Bunke et al), 66
- Contraceptives, oral, women on low-dose, lorazepam and oxazepam kinetics in (Abernethy et al), 628
- Converting enzyme inhibitor, enalapril, antihypertensive and metabolic effects of, (Chrysant et al), 741
- Corticosteroid with no systemic glucocorticoid effect after oral, intrarectal, and intranasal application: tixocortol pivalate (Laroche et al), 343
- Cumulation and sedation, repeated diazepam dosing in cirrhotic patients (Ochs et al), 471

D

- Debrisoquine, sparteine and, comparative pharmacogenetics of (Inaba et al), 394
- Depressed patients, mianserin kinetics in (Hrdina et al), 757
- Desipramine hydroxylation: variability and effect of antipsychotic drugs (Bock et al), 322

Desmethylinipramine, effects of, on plasma norepinephrine, pulse, and blood pressure (Ross et al), 429

Determination of myocardial and serum digoxin concentrations in children by specific and non-specific assay methods (Wagner et al), 577

Developmental aspects of theophylline metabolism in premature infants (Tserng et al), 522

Diabetes mellitus, noninsulin-dependent, treatment of, with enzyme inducers (Sotaniemi et al), 826

Diazepam dosing, repeated, in cirrhotic patients: cumulation and sedation (Ochs et al), 471

Diffusional disposition and hypouricemic response in osteoarthritis (Meffin et al), 813

Digitoxin kinetics and renal excretion in children (Larsen and Storstein), 717

Digoxin and calcium antagonists and antiarrhythmic drugs, interaction between (Belz et al), 410 and potassium-sparing diuretics, interactions between (Waldorff et al), 418

Dipyridamole, effects of intravenous epoprostenol on platelets and the cardiovascular system are not potentiated by (Pickles et al), 178

Disposition, amitriptyline, in young and elderly normal men (Schulz et al), 360

kinetics, lorcinide, in arrhythmia patients (Kates et al), 28

propranolol, liver blood flow and, effect of thyrotoxicosis on, after long-term dosing (Wells et al), 603

Disulfiram and erythrocyte aldehyde dehydrogenase inhibition (Towell et al), 517

Diuretic(s), potassium-sparing, digoxin and, interactions between (Waldorff et al), 418

-wasting, dose-response relationships for spironolactone in combination with a (McInnes et al), 35

Diurnal variation in prednisolone kinetics (English et al), 381

Divalproex sodium (USAN list No. 233), 190

Dose-dependent effects of cimetidine on phenytoin kinetics (Bartle et al), 649

metabolism, nonlinear mefloquine kinetics due to (Gundert-Remy et al), 656

-response relationships for spironolactone in combination with a potassium-wasting diuretic (McInnes et al), 35

Dosing, evening, with extended-release fenfluramine, patient acceptance and efficacy of (Weintraub et al), 621

long-term, effect of thyrotoxicosis on liver blood flow and propranolol disposition after (Wells et al), 603

Doxazosin mesylate (USAN list No. 233), 190

Drug(s) development, new, during and after a period of regulatory change: clinical research activity of major United States pharmaceutical firms, 1958 to 1979 (May et al), 691

metabolism, cigarette smoking and (Vähäkangas et al), 375

Drug(s)—cont'd

new, investigations and reports respecting FDA regulation of, Part II (Hutt), 674

product information in four national compendia, a comparison of (Alloza and Lasagna), 269

Dyphylline elimination, effect of probenecid on (May and Jarboe), 822

E

Effect(s), dose-dependent, of cimetidine on phenytoin kinetics (Bartle et al), 649

of alcohol on propylthiouracil disposition (Long et al), 663

of beta-adrenoceptor antagonists, central (Salem and McDevitt), 52

of caffeine on acetaminophen analgesia (Laska et al), 498

of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics (Neuvonen and Kärkkäinen), 386

of cigarette smoking and oral nicotine on hand tremor (Shiffman et al), 800

of clonidine in patients with alcohol amnesic disorder, urinary catecholamine metabolites and (Martin et al), 19

of desmethylinipramine on plasma norepinephrine, pulse, and blood pressure (Ross et al), 429

of erythromycin on carbamazepine kinetics (Wong et al), 460

of guanabenz on blood pressure responses to posture and exercise (Dziedzic et al), 151

of intravenous epoprostenol on platelets and the cardiovascular system are not potentiated by dipyridamole (Pickles et al), 178

of phenoxybenzamine on cardiovascular and plasma catecholamine responses to clonidine (Zweifler et al), 156

of phenytoin, phenobarbital, and ascorbic acid on misonidazole elimination (Williams et al), 314

of probenecid on dyphylline elimination (May and Jarboe), 822

of thyrotoxicosis on liver blood flow and propranolol disposition after long-term dosing (Wells et al), 603

of tibalosine, a new α -adrenoceptor antagonist, in essential hypertension (Staessen et al), 556

on apparent liver blood flow of histamine-receptor blockers and inhibition of prostaglandin synthesis (Feely and Wood), 91

Efficacy, drug, verapamil plasma binding: relationship to α_1 -acid glycoprotein and (McGowan et al), 485

and patient acceptance of evening dosing with extended-release fenfluramine (Weintraub et al), 621

and safety of *N*-acetylprocainamide in long-term treatment of ventricular arrhythmias (Atkinson et al), 565

- Egtazic acid (USAN list No. 237), 827
- Elderly normal men, young and, amitriptyline disposition in (Schulz et al), 360
- Elimination, dyphylline, effect of probenecid on (May and Jarboe), 822
- lidocaine: effects of metoprolol and of propranolol (Conrad et al), 133
- nadolol, enhancement of, by activated charcoal and antibiotics (Du Souich et al), 585
- Enalapril, a new converting enzyme inhibitor, antihypertensive and metabolic effects of (Chrysant et al), 741
- Endogenous norepinephrine release by tyramine, blood pressure and plasma norepinephrine concentrations after (Scriven et al), 710
- Enhancement of nadolol elimination by activated charcoal and antibiotics (Du Souich et al), 585
- of theophylline clearance by oral activated charcoal (Berlinger et al), 351
- Enterohepatic circulation of sulindac and metabolites (Dujovne et al), 172
- Enviradene (USAN list No. 237), 826
- Enzyme inhibitor, converting, enalapril, antihypertensive and metabolic effects of a new (Chrysant et al), 741
- inducers, treatment of noninsulin-dependent diabetes mellitus with (Sotaniemi et al), 826
- Epoprostenol, effects of intravenous, on platelets and the cardiovascular system are not potentiated by dipyridamole (Pickles et al), 178
- Erratum (to Martin et al), 288
- Erythrocyte aldehyde dehydrogenase inhibition, disulfiram and (Towell et al), 517
- Erythromycin, effect of, on carbamazepine kinetics (Wong et al), 460
- Essential hypertension, effects of tibolone, a new α -adrenoceptor antagonist in (Staessen et al), 556
- hemodynamic effects of labetalol in (Dunn et al), 139
- Ethotoin kinetics, nonlinear (Meyer et al), 329
- Etibendazole (USAN list No. 237), 827
- Evaluation, preclinical and clinical, of topical acid products for skin tumors (Weiner et al), 77
- Evening dosing, patient acceptance and efficacy, with extended-release fenfluramine (Weintraub et al), 621
- Evidence for cardiac β_2 -adrenoceptors in man (Brown et al), 424
- Excretion, renal, in children, digitoxin kinetics and (Larsen and Storstein), 717
- Exercise, during, and at rest, hemodynamics and leg muscle metabolism, in young healthy men after prenalterol (Dahlström et al), 701
- posture and, effect of guanabenz on blood pressure responses to (Dziedzic et al), 151
- standing, and supine plasma norepinephrine levels, tricyclic antidepressants and (Veith et al), 763
- Extended-release fenfluramine: patient acceptance and efficacy of evening dosing (Weintraub et al), 621
- F*
- Fanetizole mesylate (USAN list No. 236), 688
- FDA regulation of new drugs, Part I, investigations and reports respecting (Hutt), 537
- Part II, investigations and reports respecting (Hutt), 674
- Fencibutolol (USAN list No. 235), 549
- Fenfluramine, extended release: patient acceptance and efficacy of evening dosing (Weintraub et al), 621
- Ferrous sulfate, food, and antacid, reduction in oral penicillamine absorption by (Osman et al), 465
- Flavodilol maleate (USAN list No. 233), 191
- Flordipine (USAN list No. 236), 689
- Fludrocortisone suppression of sympathetic nervous activity (Izzo et al), 102
- Food, antacid, and ferrous sulfate, reduction in oral penicillamine absorption by (Osman et al), 465
- Free propranolol levels, total and, in sensitive and resistant patients (Steinberg and Bilezikian), 163
- Functionally anephric patients, single-dose ceftriaxone kinetics in (Stoeckel et al), 633
- G*
- Gallamine disposition in open-heart surgery involving cardiopulmonary bypass (Shanks et al), 792
- Gemeprost (USAN list No. 235), 550
- Glucocorticoid effect, no systemic, after oral, intrarectal, and intranasal application of tixocortol pivalate, a corticosteroid with (Larochelle et al), 343
- Glucose and lipid metabolism during acebutolol and propranolol therapy of angina in nondiabetic patients (Birnbaum et al), 294
- Glucose-6-phosphate dehydrogenase deficiency, microsomal incubation test of potentially hemolytic drugs for (Bloom et al), 403
- Guanabenz, effect of, on blood pressure responses to posture and exercise (Dziedzic et al), 151
- H*
- Haloperidol kinetics after oral and intravenous doses (Holley et al), 477
- Hand tremor, effects of cigarette smoking and oral nicotine on (Shiffman et al), 800
- Hemodynamic(s) effects of intravenous labetalol in essential hypertension (Dunn et al), 139
- and leg muscle metabolism at rest and during exercise in young healthy men after prenalterol (Dahlström et al), 701
- and plasma catecholamine responses to morphine, role of histamine in (Fahmy et al), 615

- Hemolytic drugs, potentially, for glucose-6-phosphate dehydrogenase deficiency, microsomal incubation test of (Bloom et al), 403
- Hepatic insufficiency, mezlocillin kinetics in (Bunke et al), 73
- Histamine-receptor blockers, effect on apparent liver blood flow of, and inhibition of prostaglandin synthesis (Feely and Wood), 91
 - role of, in the hemodynamic and plasma catecholamine responses to morphine (Fahmy et al), 615
- How a cigarette is smoked determines blood nicotine levels (Herning et al), 84
- 2-Hydroxydesipramine plasma concentrations, clinical implications of (Nelson et al), 183
- Hydroxylation, desipramine: variability and effect of antipsychotic drugs (Bock et al), 322
- Hypertension, essential, effects of tibalosine, a new α -adrenoceptor antagonist in (Staessen et al), 556
 - hemodynamic effects of intravenous labetalol in (Dunn et al), 139
 - indenolol in (Sega et al), 289
 - vasodilation therapy of, cardiac muscle mass during (Drayer et al), 727
- Hypouricemic response in osteoarthritis, diflunisal disposition and (Meffin et al), 813

I

- Imipemide (USAN list No. 235), 549
- Imipramine metabolites in blood of patients during therapy and after overdose (Gram et al), 335
- Implications, clinical, of 2-hydroxydesipramine plasma concentrations (Nelson et al), 183
- Incubation test, microsomal, of potentially hemolytic drugs for glucose-6-phosphate dehydrogenase deficiency (Bloom et al), 403
- Indenolol in hypertension (Sega et al), 289
- Infants, premature, developmental aspects of theophylline metabolism in (Tserng et al), 522
- Infusions, predicting high-dose methotrexate, test dose for (Kerr et al), 44
- Inhibition, erythrocyte aldehyde dehydrogenase, disulfiram and (Towell et al), 517
 - of prostaglandin synthesis, effect on apparent liver blood flow of histamine-receptor blockers and (Feely and Wood), 91
- Inorganic sulfate, serum concentration and renal excretion by normal adults, after acetaminophen, ascorbic acid, or sodium sulfate (Morris and Levy), 529
- Interaction(s), atenolol, with aspirin, allopurinol, and ampicillin (Schäfer-Korting et al), 283
 - between digoxin and calcium antagonists and antiarrhythmic drugs (Belz et al), 410
 - and potassium-sparing diuretics (Waldorff et al), 418
- Intermediate-dose methotrexate infusion, methotrexate cerebrospinal fluid and serum concentrations after (Evans et al), 301

- Intra-arterial profile of methylodopa (Gould et al), 438
- Intranasal, oral, and intrarectal application of tixocortol pivalate, a corticosteroid with no systemic glucocorticoid effect after (Laroche et al), 343
- Intrarectal, oral, and intranasal application of tixocortol pivalate, a corticosteroid with no systemic glucocorticoid effect after (Laroche et al), 343
- Intravenous doses, oral and, haloperidol kinetics after (Holley et al), 477
 - epoprostenol, effects of, on platelets and the cardiovascular system are not potentiated by dipyridamole (Pickles et al), 178
 - labetalol, hemodynamic effects of, in essential hypertension (Dunn et al), 139
 - sublingual, and percutaneous dosing in angina, isosorbide dinitrate kinetics and dynamics after (Morrison et al), 747
- Investigations and reports respecting FDA regulation of new drugs, Part I (Hutt), 537
 - Part II (Hutt), 674
- Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina (Morrison et al), 747

K

- Ketorfanol (USAN list No. 236), 688
- Kinetics: *see* specific drug

L

- Labetalol during long-term dosing, α -adrenoceptor blockade by (Semplicini et al), 278
 - intravenous, hemodynamic effects of, in essential hypertension (Dunn et al), 139
- Leg muscle metabolism, hemodynamics and, at rest and during exercise in young healthy men after prenalterol (Dahlström et al), 701
- Lidocaine elimination: effects of metoprolol and of propranolol (Conrad et al), 133
- Lipid metabolism, glucose and, during acebutolol and propranolol therapy of angina in nondiabetic patients (Birnbaum et al), 294
- Liver blood flow and propranolol disposition, effect of thyrotoxicosis on, after long-term dosing (Wells et al), 603
 - disease, chronic, acetaminophen in (Benson), 95
- Local aspirin analgesia in the oral cavity (Loch et al), 642
- Long-term dosing, α -adrenoceptor blockade by labetalol during (Semplicini et al), 278
 - effect of thyrotoxicosis on liver blood flow and propranolol disposition after (Wells et al), 603
 - treatment of ventricular arrhythmias, efficacy and safety of *N*-acetylprocainamide in (Atkinson et al), 565
- Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives (Abernethy et al), 628

Lorcainide disposition kinetics in arrhythmia patients (Kates et al), 28

Low-dose oral contraceptives, lorazepam and oxazepam kinetics in women on (Abernethy et al), 628

M

Maternal midazolam kinetics, placental transfer and (Kanto et al), 786

Mefenidil fumarate (USAN list No. 237), 826

Metabolic and antihypertensive effects of a new converting enzyme inhibitor, enalapril (Chrysant et al), 741

Metabolism, caffeine, and coffee-attributed sleep disturbances (Levy and Zylber-Katz), 770
variability in (Grant et al), 591

dose-dependent, nonlinear mezlocillin kinetics due to (Gundert-Remy et al), 656

drug, cigarette smoking and (Vähäkangas et al), 375

glucose and lipid, during acebutolol and propranolol therapy of angina in nondiabetic patients (Birnbbaum et al), 294

leg muscle, hemodynamics and, at rest and during exercise in young healthy men after prenal-terol (Dahlström et al), 701

of sulfipyrazone, kinetics and (Mahony et al), 491

single-dose kinetics and, of carbamazepine-10,11-epoxide (Tomson et al), 58

theophylline, developmental aspects of, in premature infants (Tserng et al), 522

Metabolite(s), caffeine, polymorphic *N*-acetylation of a (Grant et al), 355

imipramine, in blood of patients during therapy and after overdose (Gram et al), 335

sulindac and, enterohepatic circulation of (Dujovne et al), 172

urinary catecholamine, and effects of clonidine in patients with alcohol amnesic disorder (Martin et al), 19

Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion (Evans et al), 301

infusion(s), intermediate-dose, methotrexate cerebrospinal fluid and serum concentrations after (Evans et al), 301

high-dose, test dose for predicting (Kerr et al), 44

Methyldopa, an intra-arterial profile of (Gould et al), 438

Metoprolol and propranolol, effects of, in lidocaine elimination (Conrad et al), 133

Mezlocillin kinetics in hepatic insufficiency (Bunke et al), 73

nonlinear, due to dose-dependent metabolism (Gundert-Remy et al), 656

Mianserin kinetics in depressed patients (Hrdina et al), 757

Microsomal incubation test of potentially hemolytic drugs for glucose-6-phosphate dehydrogenase deficiency (Bloom et al), 403

Midazolam kinetics, maternal, placental transfer and (Kanto et al), 786

Misonidazole elimination, effects of phenytoin, phenobarbital, and ascorbic acid on (Williams et al), 314

Mitindomide (USAN list No. 236), 688

Monobactam, the, azthreonam, renal handling of, in healthy subjects (Swabb et al), 609

Morphine, hemodynamic and plasma catecholamine responses to, role of histamine in (Fahmy et al), 615

Muscle mass, cardiac, during vasodilation therapy of hypertension (Drayer et al), 727

Myocardial and serum digoxin concentrations in children, determination of, by specific and nonspecific assay methods (Wagner et al), 577

N

N-Acetylation, polymorphic, of a caffeine metabolite (Grant et al), 355

N-Acetylprocainamide in long-term treatment of ventricular arrhythmias, efficacy and safety of (Atkinson et al), 565

Nadolol elimination by activated charcoal and antibiotics, enhancement of (Du Souich et al), 585

Nalmefene (USAN list No. 234), 400

National compendia, four, a comparison of drug product information in (Alloza and Lasagna), 269

Neonate, toward optimization of therapy in (Rajchgot et al), 551

New drug(s) development during and after a period of regulatory change: Clinical research activity of major United States pharmaceutical firms, 1958 to 1979 (May et al), 691
investigations and reports respecting FDA regulation of, Part II (Hutt), 674

Part I, investigations and reports respecting FDA regulation of (Hutt), 537

Nicotine levels, blood, how a cigarette is smoked determines (Herning et al), 84

oral, and cigarette smoking, effects of, on hand tremor (Shiffman et al), 800

Nizatidine (USAN list No. 234), 400

Nondiabetic patients, angina in, glucose and lipid metabolism during acebutolol and propranolol therapy of (Birnbbaum et al), 294

Noninsulin-dependent diabetes mellitus, treatment of, with enzyme inducers (Sotaniemi et al), 826

Nonlinear ethotoin kinetics (Meyer et al), 329
mezlocillin kinetics due to dose-dependent metabolism (Gundert-Remy et al), 656

- Norepinephrine concentrations, plasma, blood pressure and, after endogenous norepinephrine release by tyramine (Scriven et al), 710
- levels, plasma, supine, standing, and exercise, tricyclic antidepressants and (Veith et al), 763
- release, endogenous, by tyramine, blood pressure and plasma norepinephrine concentrations after (Scriven et al), 710

O

- Obesity, platelet alpha-adrenergic receptors in, alteration with weight loss (Sundaresan et al), 776
- Open-heart surgery involving cardiopulmonary bypass, gallamine disposition in (Shanks et al), 792
- Optimization of therapy in the neonate, toward (Rajchgot et al), 551
- Oral activated charcoal, enhancement of theophylline clearance by (Berlinger et al), 351
- cavity, local aspirin analgesia in (Loch et al), 642
- contraceptives, women on low-dose, lorazepam and oxazepam kinetics in (Abernethy et al), 628
- intrarectal, and intranasal application of tixocortol pivalate, a corticosteroid with no systemic glucocorticoid effects after (Laroche et al), 343
- and intravenous doses, haloperidol kinetics after (Holley et al), 477
- penicillamine absorption, reduction in, by food, antacid, and ferrous sulfate (Osman et al), 465
- Osteoarthritis, diflunisal disposition and hypouricemic response in (Meffin et al), 813
- Overdose, after, during therapy and, imipramine metabolites in blood of patients (Gram et al), 335
- Oxazepam and lorazepam kinetics in women on low-dose oral contraceptives (Abernethy et al), 628

P

- Pafenolol, a highly selective β_1 -adrenoceptor-antagonist, in asthmatic patients: interaction with terbutaline (Löfdahl et al), 1
- Patient acceptance and efficacy of evening dosing with extended-release fenfluramine (Weintraub et al), 621
- Pentobarbital, effects of, on cigarette smoking and subjective response in alcoholics (Hennigfield et al), 806
- Percutaneous, intravenous, and sublingual dosing in angina, isosorbide dinitrate kinetics and dynamics after (Morrison et al), 747

- Pharmaceutical firms, major, United States, clinical research activity of, new drug development during and after a period of regulatory change, 1958 to 1979 (May et al), 691
- Pharmacogenetics, comparative, of sparteine and debrisoquine (Inaba et al), 394
- Phenobarbital, ascorbic acid, and phenytoin, effects of, on misonidazole elimination (Williams et al), 314
- Phenoxybenzamine, effect of, on cardiovascular and plasma catecholamine responses to clonidine (Zweifler et al), 156
- Phenytoin kinetics, dose-dependent effects of cimetidine on (Bartle et al), 649
- phenobarbital, and ascorbic acid, effects of, on misonidazole elimination (Williams et al), 314
- Pindolol, long-term blockade with, constant kinetics and constant concentration-effect relationship during (Galeazzi et al), 733
- Placental transfer and maternal midazolam kinetics (Kanto et al), 786
- Plasma binding, verapamil: relationship to α_1 -acid glycoprotein and drug efficacy (McGowan et al), 485
- catecholamine responses, hemodynamic and, to morphine, role of histamine in (Fahmy et al), 615
- to clonidine, cardiovascular and, effect of phenoxybenzamine on (Zweifler et al), 156
- concentration-effect relationship, alcuronium kinetics and (Walker et al), 510
- 2-hydroxydesipramine, clinical implications of (Nelson et al), 183
- norepinephrine, concentrations, blood pressure and, after endogenous norepinephrine release by tyramine (Scriven et al), 710
- levels, supine, standing, and exercise, tricyclic antidepressants and (Veith et al), 763
- pulse, and blood pressure, effects of desmethylimipramine on (Ross et al), 429
- Plasma propranolol, urine and (Andreassen et al), 10
- Platelet(s) aggregation in man, aspirin kinetics and (Siebert et al), 367
- alpha-adrenergic receptors in obesity: alteration with weight loss (Sundaresan et al), 776
- and the cardiovascular system, effects of intravenous epoprostenol on, are not potentiated by dipyridamole (Pickles et al), 178
- Polymorphic N-acetylation of a caffeine metabolite (Grant et al), 355
- Posture and exercise, effect of guanabenz on blood pressure responses to (Dziedzic et al), 151
- Potassium-sparing diuretics, digoxin and, interactions between (Waldorff et al), 418
- wasting diuretic, dose-response relationships for spironolactone in combination with a (McInnes et al), 35

- Preclinical and clinical evaluation of topical acid products for skin tumors (Weiner et al), 77
- Prednicarbate (USAN list No. 236), 689
- Prednisolone kinetics, diurnal variation in (English et al), 381
- Prenalterol, hemodynamics and leg muscle metabolism at rest and during exercise in young healthy men after (Dahlström et al), 701
- Probenecid, effect of, on dipyridine elimination (May and Jarboe), 822
- Propranolol disposition and liver blood flow, effect of thyrotoxicosis on, after long-term dosing (Wells et al), 603
- effects of metoprolol and, in lidocaine elimination (Conrad et al), 133
- levels, total and free, in sensitive and resistant patients (Steinberg and Bilizikian), 163
- therapy, acebutolol and, of angina in nondiabetic patients, glucose and lipid metabolism during (Birnbaum et al), 294
- Propylthiouracil disposition, effect of alcohol on (Long et al), 663
- Prostaglandin synthesis, inhibition of, effect on apparent liver blood flow of histamine-receptor blockers and (Feely and Wood), 91
- Pulse, plasma norepinephrine, and blood pressure, effects of desmethylimipramine on (Ross et al), 429
- R**
- Ranitidine bioavailability and kinetics in normal male subjects (Garg et al), 445
- Receptors, platelet α -adrenergic, in obesity: alteration with weight loss (Sundaresan et al), 776
- Reduction in oral penicillamine absorption by food, antacid, and ferrous sulfate (Osman et al), 465
- Regulation of new drugs, FDA, investigations and reports respecting, Part II (Hutt), 674
- Regulatory change, new drug development during and after a period of: clinical research activity of major United States pharmaceutical firms, 1958 to 1979 (May et al), 691
- Relationship, plasma concentration-effect, alcuronium kinetics and (Walker et al), 510
- to α_1 -acid glycoprotein and drug efficacy, verapamil plasma binding (McGowan et al), 485
- Renal excretion in children, digitoxin kinetics and (Larsen and Storstein), 717
- serum concentration and, by normal adults of inorganic sulfate after acetaminophen, ascorbic acid, or sodium sulfate (Morris and Levy), 529
- handling of the monobactam azthreonam in healthy subjects (Swabb et al), 609
- insufficiency, bretylium kinetics in (Joselson et al), 144
- Repeated diazepam dosing in cirrhotic patients: cumulation and sedation (Ochs et al), 471
- Reports, investigations and, respecting FDA regulation of new drugs, Part I (Hutt), 537
- Part II (Hutt), 674
- Research activity of major United States pharmaceutical firms, 1958 to 1979, new drug development during and after a period of regulatory change (May et al), 691
- Resistant patients, sensitive and, total and free propranolol levels in (Steinberg and Bilizikian), 163
- Response(s) in alcoholics, subjective, cigarette smoking and: effects of pentobarbital (Henningfield et al), 806
- to morphine, hemodynamic and plasma catecholamine, role of histamine in (Fahmy et al), 615
- Rest and during exercise, hemodynamics and leg muscle metabolism at, in young healthy men after prenalterol (Dahlström et al), 701
- Rioprostil (USAN list No. 235), 550
- Role of histamine in the hemodynamic and plasma catecholamine responses to morphine (Fahmy et al), 615
- S**
- Safety and efficacy of *N*-acetylprocainamide in long-term treatment of ventricular arrhythmias (Atkinson et al), 565
- Sedation, cumulation and, repeated diazepam dosing in cirrhotic patients (Ochs et al), 471
- Sensitive and resistant patients, total and free propranolol levels in (Steinberg and Bilizikian), 163
- Sertraline hydrochloride (USAN list No. 237), 827
- Serum concentration and renal excretion by normal adults of inorganic sulfate after acetaminophen, ascorbic acid, or sodium sulfate (Morris and Levy), 529
- falls, chloramphenicol, during chloramphenicol succinate dosing (Nahata and Powell), 308
- methotrexate cerebrospinal fluid and, after intermediate-dose methotrexate infusion (Evans et al), 301
- digoxin concentrations, myocardial and, determination of, in children, by specific and nonspecific assay methods (Wagner et al), 577
- Single-dose ceftriaxone kinetics in functionally anephric patients (Stoeckel et al), 633
- kinetics and metabolism of carbamazepine-10,11-epoxide (Tomson et al), 58
- Skin tumors, topical acid products for, preclinical and clinical evaluation of (Weiner et al), 77
- Sleep disturbances, coffee-attributed, caffeine metabolism and (Levy and Zylber-Katz), 770
- Smoking, cigarette, and drug metabolism (Vähäkangas et al), 375

Smoking—cont'd

- and oral nicotine, effects of, on hand tremor (Shiffman et al), 800
- and subjective response in alcoholics: effects of pentobarbital (Henningfield et al), 806
- Sodium bicarbonate, charcoal, and ammonium chloride, effects of, on chlorpropamide kinetics (Neuvonen and Kärkkäinen), 386
- sulfate, acetaminophen, or ascorbic acid, serum concentration and renal excretion by normal adults of inorganic sulfate after (Morris and Levy), 529
- Sparteine and debrisoquine, comparative pharmacogenetics of (Inaba et al), 394
- Spironolactone, dose-response relationships for, in combination with a potassium-wasting diuretic (McInnes et al), 35
- Spiroplatin (USAN list No. 232), 107
- Standing, exercise, and supine plasma norepinephrine levels, tricyclic antidepressants and (Veith et al), 763
- Subjective response in alcoholics, cigarette smoking and: effects of pentobarbital (Henningfield et al), 806
- Sublingual, percutaneous, and intravenous dosing in angina, isosorbide dinitrate kinetics and dynamics after (Morrison et al), 747
- Sulfinpyrazone, kinetics and metabolism of (Mahony et al), 491
- Sulindac and metabolites, enterohepatic circulation of (Dujovne et al), 172
- Supine, standing, and exercise plasma norepinephrine levels, tricyclic antidepressants and (Veith et al), 763
- Surgery, open-heart, involving cardiopulmonary bypass, gallamine disposition in (Shanks et al), 792
- Sympathetic nervous activity, fludrocortisone suppression of (Izzo et al), 102
- Systemic glucocorticoid effect, no, after oral, intrarectal, and intranasal application of tixocortol pivalate, a corticosteroid with (Laroche et al), 343

T

- Terbutaline, interaction with pafenolol, a highly selective β_1 -adrenoceptor-antagonist in asthmatic patients (Löfdahl et al), 1
- Test dose for predicting high-dose methotrexate infusions (Kerr et al), 44
- Theophylline clearance, enhancement of, by oral activated charcoal (Berlinger et al), 351
- metabolism in premature infants, developmental aspects of (Tserng et al), 522
- during, and after overdose, imipramine metabolites in blood of patients (Gram et al), 335
- in the neonate, toward optimization of (Rajchgot et al), 551

Theophylline—cont'd

- vasodilation, of hypertension, cardiac muscle mass during (Drayer et al), 727
- Thyrotoxicosis, effect of, on liver blood flow and propranolol disposition after long-term dosing (Wells et al), 603
- Tibalosine, a new α -adrenoceptor antagonist, effects of, in essential hypertension (Staessen et al), 556
- Ticabesone propionate (USAN list No. 232), 108
- Tinabitol (USAN list No. 235), 550
- Tixocortol pivalate, a corticosteroid with no systemic glucocorticoid effect after oral, intrarectal, and intranasal application (Laroche et al), 343
- Topical acid products for skin tumors, preclinical and clinical evaluation of (Weiner et al), 77
- Total and free propranolol levels in sensitive and resistant patients (Steinberg and Bilezikian), 163
- Toward optimization of therapy in the neonate (Rajchgot et al), 551
- Treatment, long-term, of ventricular arrhythmias, efficacy and safety of *N*-acetylprocainamide in (Atkinson et al), 565
- Treatment of noninsulin-dependent diabetes mellitus with enzyme inducers (Sotaniemi et al), 826
- Tricyclic antidepressants and supine, standing, and exercise plasma norepinephrine levels (Veith et al), 763
- Trimoprostil (USAN list No. 235), 550
- Tumor, hand, effects of cigarette smoking and oral nicotine on (Shiffman et al), 800
- Tumors, skin, topical acid products for, preclinical and clinical evaluation of (Werner et al), 77
- Tyramine, endogenous norepinephrine release by, blood pressure and plasma norepinephrine concentrations after (Scriven et al), 710

U

- United States pharmaceutical firms, major, clinical research activity of, new drug development during and after a period of regulatory change, 1958 to 1979 (May et al), 691
- Urinary catecholamine metabolites and effects of clonidine in patients with alcohol amnestic disorder (Martin et al), 19
- Urine and plasma propranolol (Andreassen et al), 10

V

- Variability and effect of antipsychotic drugs on desipramine hydroxylation (Bock et al), 322
- in caffeine metabolism (Grant et al), 591
- Vasodilation therapy of hypertension, cardiac muscle mass during (Drayer et al), 727
- Ventricular arrhythmias, efficacy and safety of *N*-acetylprocainamide in long-term treatment of (Atkinson et al), 565

Verapamil plasma binding: relationship to α_1 -acid glycoprotein and drug efficacy (McGowan et al), 485

Vinafocon A (USAN list No. 233), 191

Viroxime (USAN list No. 234), 400

W

Weight loss, alteration with, platelet alpha-adrenergic receptors in obesity (Sundaresan et al), 776

X

Xorphanol mesylate (USAN list No. 232), 107

Y

Young and elderly normal men, amitriptyline disposition in (Schulz et al), 360

Z

Zolazepam hydrochloride (USAN list No. 232), 107

